Asthma / Relvar Ellipta
Relvar Ellipta 22mcg + 92mcg 30doses powder
|22mcg + 92mcg 30doses powder x 1 inhaler||$88.90||$88.90||-||add to cart|
|22mcg + 92mcg 30doses powder x 3 inhalers||$65.77||$197.30||$69.40||add to cart|
|22mcg + 92mcg 30doses powder x 5 inhalers||$57.80||$289.00||$155.50||add to cart|
Relvar Ellipta 22mcg + 184mcg 30doses powder
|22mcg + 184mcg 30doses powder x 1 inhaler||$98.90||$98.90||-||add to cart|
|22mcg + 184mcg 30doses powder x 3 inhalers||$88.11||$264.32||$32.38||add to cart|
|22mcg + 184mcg 30doses powder x 5 inhalers||$77.50||$387.50||$107.00||add to cart|
Asthma: a drug Relvar of Ellipta used as maintenance therapy of bronchial asthma;
COPD (chronic obstructive pulmonary disease): drug Relvar of Ellipta used as maintenance therapy of airway obstruction in patients with COPD, including chronic bronchitis and/or emphysema. The use of the drug Relvar of Ellipta allows to reduce the number of exacerbations COPD patients with repeated exacerbations in history.
Adults and adolescents 12 years and older
The recommended dose of the drug Relvar of Ellipta:
one inhalation mcg 22+92 mcg 1 times/day
or one inhalation mcg 22+184 mcg 1 times/day.
The initial dose of the drug Relvar of Ellipta 22 mcg+92 µg assigned to patients who require low or medium doses of inhaled corticosteroids used in combination with beta2-agonists long-acting.
Drug Relvar of Ellipta at a dosage of 22 micrograms+184 mcg should be prescribed to the patients who need higher doses of inhaled corticosteroids used in combination with beta2-agonists long-acting.
If the drug Relvar of Ellipta in the dose of 22 mcg+92 mcg does not adequately control the disease, the issue about increasing the dose to 22 mcg+184 micrograms, which can improve the level of control over bronchial asthma.
patients with a history of severe allergic reaction to milk protein or hypersensitivity to the active substances or to any component included in the product;
— children up to 12 years for the treatment of asthma;
— preparation of Relvar Ellipta at a dose of 22 µg+184 mcg/dose is not indicated for the treatment of COPD.
Caution: when taking sympathomimetics, including drug Relvar of Ellipta, on the part of the cardiovascular system may occur such undesirable phenomena as arrhythmia (e.g., supraventricular tachycardia and extrasystoles). In this regard, patients suffering from severe forms of cardiovascular diseases, drug Relvar of Ellipta should be administered with caution.
Like other drugs, which include corticosteroids, drug Relvar of Ellipta should be used with caution in patients with pulmonary tuberculosis and patients with chronic infections or unbaked.
To determine the incidence of adverse reactions associated with the drug Relvar of Ellipta used data from a large clinical studies among patients with COPD and bronchial asthma. The clinical development of the drug for the treatment of asthma consisted of 7034 patients in whom conducted a comprehensive assessment of adverse reactions. In the program of clinical development of the drug for the treatment of COPD participated 6237 patients who have conducted a comprehensive assessment of adverse reactions.
The exception of pneumonia and fractures, the safety profile of the drug in patients with COPD and asthma were similar. According to clinical studies, pneumonia and fractures were more frequent in patients with COPD.
Adverse reactions, presented below, listed according to the organ and organ system and frequency. The frequency of occurrence is defined as follows: very common (?1/10). often (?1/100 and <1/10). not often (?1/1000 and <1/100), rare (?1/10 000 and <1/1000), very rare (<1/10 000. including isolated cases).
The incidence of adverse reactions
Infectious and parasitic diseases: often with pneumonia, upper respiratory tract infection, bronchitis, influenza, candidiasis of the oral cavity and pharynx.
From the nervous system: very often - headache.
Heart problems: infrequently - arrhythmia.
The respiratory system of the chest and mediastinum: very often - nasopharyngitis; often - oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, dysphonia.
By the blood: often - pain in the abdomen.
From the musculoskeletal and connective tissue: often - arthralgia. back pain, fractures.
General disorders injection site: often - fever.
Data post-marketing surveillance
Violations by the immune system: rarely - hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria.
Psychiatric disorders: rare - anxiety.
From the nervous system: rarely - tremor.
Heart: rarely - palpitations, tachycardia.